Comment
doi: 10.1016/j.expneurol.2011.07.006.
Epub 2011 Jul 30.
5-HT(1A) receptor stimulation and L-DOPA-induced dyskinesia in Parkinson's disease: bridging the gap between serotonergic and glutamatergic mechanisms
Affiliations
- PMID: 21819982
- DOI: 10.1016/j.expneurol.2011.07.006
Item in Clipboard
Comment
5-HT(1A) receptor stimulation and L-DOPA-induced dyskinesia in Parkinson's disease: bridging the gap between serotonergic and glutamatergic mechanisms
Exp Neurol.
2011 Oct.
No abstract available
Comment on
-
Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.Exp Neurol. 2011 Jun;229(2):288-99. doi: 10.1016/j.expneurol.2011.02.012. Epub 2011 Feb 22. Exp Neurol. 2011. PMID: 21352823 Free PMC article.
Similar articles
-
Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.Exp Neurol. 2011 Jun;229(2):288-99. doi: 10.1016/j.expneurol.2011.02.012. Epub 2011 Feb 22. Exp Neurol. 2011. PMID: 21352823 Free PMC article.
-
The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.Neuropharmacology. 2016 Jun;105:651-660. doi: 10.1016/j.neuropharm.2016.01.013. Epub 2016 Jan 9. Neuropharmacology. 2016. PMID: 26777281
-
Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.Neuropharmacology. 2015 Jun;93:52-67. doi: 10.1016/j.neuropharm.2015.01.012. Epub 2015 Jan 31. Neuropharmacology. 2015. PMID: 25645393
-
Serotonergic action on dorsal striatal function.Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S129-31. doi: 10.1016/S1353-8020(11)70040-2. Parkinsonism Relat Disord. 2012. PMID: 22166410 Review.
-
Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies.Biomed Pharmacother. 2015 Mar;70:283-93. doi: 10.1016/j.biopha.2015.01.029. Epub 2015 Feb 7. Biomed Pharmacother. 2015. PMID: 25776513 Review.
Cited by
-
Modulation of L-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus.Neuropharmacology. 2015 Aug;95:215-25. doi: 10.1016/j.neuropharm.2015.03.008. Epub 2015 Mar 25. Neuropharmacology. 2015. PMID: 25817388 Free PMC article.
-
Endocannabinoid-dopamine interactions in striatal synaptic plasticity.Front Pharmacol. 2012 Apr 19;3:66. doi: 10.3389/fphar.2012.00066. eCollection 2012. Front Pharmacol. 2012. PMID: 22529814 Free PMC article.
-
Levodopa-induced dyskinesias in Parkinson's disease: emerging treatments.Neuropsychiatr Dis Treat. 2013;9:1605-17. doi: 10.2147/NDT.S36693. Epub 2013 Oct 22. Neuropsychiatr Dis Treat. 2013. PMID: 24174877 Free PMC article. Review.
-
Anatomy of Graft-induced Dyskinesias: Circuit Remodeling in the Parkinsonian Striatum.Basal Ganglia. 2012 Mar 1;2(1):15-30. doi: 10.1016/j.baga.2012.01.002. Epub 2012 Feb 11. Basal Ganglia. 2012. PMID: 22712056 Free PMC article.
-
Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection.Mol Neurodegener. 2015 Apr 8;10:17. doi: 10.1186/s13024-015-0012-0. Mol Neurodegener. 2015. PMID: 25888232 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
